Mahamaya Lifesciences IPO GMP, Price, Allotment & Listing Date Details
Discover Mahamaya Lifesciences IPO details including GMP, price, date, allotment status, listing date. Check its financials with finowings IPO analysis.
Shivam.Finowings The Mahamaya Lifesciences IPO is set to open for subscription on November 11, 2025, and will close on November 13, 2025. This IPO has attracted attention in the SME segment due to its strong fundamentals and investor interest in the healthcare and lifesciences space. Let’s take a detailed look at the Mahamaya Lifesciences IPO GMP, issue details, and expected listing performance.
Mahamaya Lifesciences IPO Details
Mahamaya Lifesciences IPO is a book-built issue worth ₹70.44 crores, comprising a fresh issue of 0.56 crore shares aggregating to ₹64.28 crores and an offer for sale (OFS) of 0.05 crore shares totaling ₹6.16 crores.
-
IPO Opening Date: November 11, 2025
-
IPO Closing Date: November 13, 2025
-
Allotment Date: November 14, 2025
-
Listing Date (Tentative): November 18, 2025
-
Exchange: BSE SME
-
Issue Size: ₹70.44 Crores
-
Price Band: ₹108 – ₹114 per share
-
Lot Size: 1,200 shares
For retail investors, the minimum investment amount is ₹2,73,600 (for 2 lots or 2,400 shares at the upper price band). For HNI investors, the minimum lot size is 3 lots (3,600 shares), amounting to ₹4,10,400.
Mahamaya Lifesciences IPO GMP Today
As of November 10, 2025 (09:43 AM), the Mahamaya Lifesciences IPO GMP (Grey Market Premium) stands at ₹0. With a price band of ₹114, the estimated listing price is ₹114 per share, indicating no premium or discount in the grey market currently.
This shows a neutral sentiment among grey market traders ahead of the listing. However, GMP trends can shift quickly based on subscription figures, QIB participation, and overall market mood.
Mahamaya Lifesciences IPO GMP Trend & Analysis
In the last seven sessions of grey market activity, no significant movement has been observed in the GMP. This stable trend suggests that the IPO is yet to see strong speculative action in the unlisted space.
While a ₹0 GMP might look unexciting, it can often change after subscription data is revealed. Historically, SME IPOs with strong fundamentals and good retail participation have shown upward movement closer to listing day.
At Finowings, we update IPO GMP daily to help investors stay informed about real-time market sentiment and expected listing prices.
Expected Listing & Investment Outlook
Given the neutral GMP and moderate issue size, the Mahamaya Lifesciences IPO might see a stable debut near its issue price, provided the subscription numbers remain balanced across retail and HNI categories.
Investors may consider evaluating the company’s financial performance, sector growth potential, and valuation metrics before making a final investment decision. The lifesciences sector continues to attract investor interest due to its long-term growth outlook, which could benefit Mahamaya Lifesciences post-listing.
Conclusion
The Mahamaya Lifesciences IPO GMP currently stands at ₹0, indicating steady market sentiment. With its ₹70.44 crore issue, competitive price band, and presence in the lifesciences segment, the IPO will be worth watching once subscriptions open.
Stay tuned with Finowings for daily GMP updates, subscription status, and the expected listing price of Mahamaya Lifesciences IPO.
